Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson's disease
Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson's disease Herantis Pharma PlcCompany release 27 Sep 2017 at 9:00 am Herantis Pharma Plc ("Herantis") has initiated patient recruitment in the first-in-human clinical study of the company's investigational product CDNF for the treatment of Parkinson's disease. The first study site, Karolinska University Hospital in Stockholm, Sweden, has already consented the first patient in the study. "It is highly rewarding to reach this milestone after years of determined effort by our team,